Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Cited by (6,144)

Items 501–600 of 6,144

1. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
   Hua Ling Sun, Ronald M. Krauss, Jeffrey T. Chang, Ba‐Bie Teng · 2017 · Journal of Lipid Research
2. A polygenic risk score predicts atrial fibrillation in cardiovascular disease
   Nicholas Marston, Amanda C. Garfinkel, Frederick Kamanu, Giorgio E. M. Melloni, Carolina Roselli, Petr Jarolím, David D. Berg, Deepak L. Bhatt, Marc P. Bonaca, Christopher Paul Cannon et al. · 2022 · European Heart Journal
3. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
   Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie Mitchell Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew Jay Budoff, Javed Butler, David Z.I. Cherney et al. · 2024 · Metabolism
4. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
   Connie Ng Hess, Cecilia C. Low Wang, William R. Hiatt · 2017 · Annual Review of Medicine
5. Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis
   Linn Charlotte Andelius, Martin Bødtker Mortensen, Bjarne Linde Nørgaard, Jawdat Abdulla · 2018 · European Heart Journal - Cardiovascular Imaging
6. Statin-Associated Muscle Disease: Advances in Diagnosis and Management
   Beth A. Taylor, Paul D. Thompson · 2018 · Neurotherapeutics
7. Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
   Paul D. Rosenblit · 2019 · Current Diabetes Reports
8. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
   Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali Al‐Hashimi, Šárka Lhoták, Melissa E. MacDonald, Aurora Mejía‐Benítez, Annik Prat, Suleiman A. Igdoura, Bernardo L. Trigatti et al. · 2019 · JHEP Reports
9. Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China
   Chengping Hu, Jianwei Zhang, Jinxing Liu, Yan Liu, Ang Gao, Yong Zhu, Yingxin Zhao · 2020 · Cardiovascular Diabetology
10. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
    PRAKASH C. DEEDWANIA, Sabina A. Murphy, André Jacques Scheen, Jolita Badarienė, Armando Lira Pineda, Narimon Honarpour, ANTHONY C. KEECH, Peter Sever, Terje Rolf Pedersen, Marc Steven Sabatine et al. · 2020 · JAMA Cardiology
11. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
    Peter Edward Penson, Éric Bruckert, DAVID P. MARAIS, Željko Reiner, Matteo Pirro, Amirhossein Sahebkar, Gani Bajraktari, Erkin Mirsaidovich Mirrakhimov, Manfredi Rizzo, Dimitri P. Mikhailidis et al. · 2022 · Journal of Cachexia Sarcopenia and Muscle
12. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
    Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, Børge Grønne Nordestgaard, Carl E. Orringer · 2022 · Journal of clinical lipidology
13. Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China
    Chen, Liang, Chen, Shi, Bai, Xueke, Su, Mingming, He, Linkang, Li, Guangyu, He, Guangda, Yang, Yang, Zhang, Xiaoyan, Cui, Jianlan et al. · 2024 · JAMA Network Open
14. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
    Falk W. Lohoff, Jill L. Sorcher, Allison D. Rosen, Kelsey L. Mauro, R R Fanelli, Reza Momenan, Colin A. Hodgkinson, Leandro Franco Vendruscolo, George F. Koob, Melanie L. Schwandt et al. · 2017 · Molecular Psychiatry
15. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
    William E. Boden, Deepak L. Bhatt, Peter Paul Toth, Kausik Kumar Ray, M. John Chapman, Thomas Felix Lüscher · 2019 · European Heart Journal
16. Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art
    Alexios S. Antonopoulos, Andreas Angelopoulos, Konstantinos P Tsioufis, Charalambos A. Antoniades, Dimitris Tousoulis · 2021 · European Journal of Preventive Cardiology
17. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
    Yu. A. Vasyuk, Gennadii Efimovich Gendlin, Elena Ivanovna Emelina, E. Yu. Shupenina, Marina F. Ballyuzek, И. В. Баринова, Marina V. Vitsenya, Igor Leonidovich Davydkin, Дундуа Давид Петрович, Dmitry Viktorovich Duplyakov et al. · 2021 · Russian Journal of Cardiology
18. Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis
    Christin G. Hong, Elizabeth M. Florida, Haiou Li, Philip M. Parel, Nehal N. Mehta, Alexander V. Sorokin · 2023 · Frontiers in Cardiovascular Medicine
19. VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients
    Takahiro Horie, Koh Ono · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
20. Evolving targets for the treatment of atherosclerosis
    Ankita Solanki, Lokesh Kumar Bhatt, Thomas Patrick Johnston · 2018 · Pharmacology & Therapeutics
21. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes
    Stahel, Priska, Xiao, Changting, Hegele, Robert A., Lewis, Gary F. · 2018 · Canadian Journal of Cardiology
22. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
    Francesco Paciullo, Stefania Momi, Paolo Gresele · 2019 · Thrombosis and Haemostasis
23. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry
    Paul Barton Duell, Samuel S. Gidding, Rolf L. Andersen, Thomas Knickelbine, Lars Anderson, Eugenia Gianos, Peter J. Shrader, Iris Kindt, Emily Claire O'Brien, Dervilla McCann et al. · 2019 · Atherosclerosis
24. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk
    Borja E. Sanz-Cuesta, Jeffrey L. Saver · 2021 · Stroke
25. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi · 2022 · Diabetes & Metabolism Journal
26. An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
    Koren, Michael J., Rodriguez, Fatima, East, Cara, Toth, Peter P., Watwe, Veena, Abbas, Cheryl A., Sarwat, Samiha, Kleeman, Kelly, Kumar, Biswajit, Ali, Yousuf et al. · 2024 · Journal of the American College of Cardiology
27. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association
    Eugenia Gianos, Paul Barton Duell, Peter Paul Toth, Patrick M. Moriarty, Gilbert R. Thompson, Eliot A. Brinton, Lisa Cooper Hudgins, Mary Nametka, Kathleen Byrne, Geetha Raghuveer et al. · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
28. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
    Kimberly N. Hong, Valentı́n Fuster, Robert S. Rosenson, Clive Rosendorff, Deepak L. Bhatt · 2017 · Journal of the American College of Cardiology
29. Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies
    Ruurt Jukema, Tarek Abdel-Hameed Nagib Ahmed, Jean‐Claude Tardif · 2019 · BMC Medicine
30. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia
    Antonio Gallo, Leopoldo Pérez de Isla, Sybil Charrière, Alexandre Vimont, Rodrigo Alonso K, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Daniel Zambón, Philippe Moulin, Éric Bruckert et al. · 2021 · JACC. Cardiovascular imaging
31. The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
    Katharina Andrea Schuett, Nikolaus Marx, Michael Lehrke · 2023 · Circulation Research
32. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study
    Kausik Kumar Ray, Carlos Aguíar, Marcello Arca, Derek Leslie Connolly, Mats Eriksson, Jean Ferrières, Ulrich Laufs, José M. Mostaza, David Nanchen, A. Bardet et al. · 2024 · European Journal of Preventive Cardiology
33. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
    Stefano Romeo, Antonio Vidal‐Puig, Mansoor Husain, Rexford S. Ahima, Marcello Arca, Deepak L. Bhatt, Anna Mae Diehl, Luigi Fontana, Roger Foo, Gema Frühbeck et al. · 2025 · European Heart Journal
34. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
    Frank L.J. Visseren, François Mach, Yvo Michiel Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Bénétos, Alessandro Biffi, José Manuel Boavida, Davide Capodanno et al. · 2022 · Revista Española de Cardiología
35. Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
    Wang, Nelson, Woodward, Mark, Huffman, Mark D., Rodgers, Anthony · 2022 · Circulation: Cardiovascular Quality and Outcomes
36. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
    Flavio Giuseppe Biccirè, Jonas Dominik Häner, Sylvain Losdat, Yasushi Ueki, Hiroki Shibutani, Tatsuhiko Otsuka, Ryota Kakizaki, Thomas Martin Hofbauer, Robert‐Jan van Geuns, Stefan Stortecky et al. · 2023 · Journal of the American College of Cardiology
37. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol F. Kirkpatrick, Kevin Carl Maki, Peter Paul Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave L. Dixon, Terry A. Jacobson · 2024 · Obesity Pillars
38. The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
    Nathan K. P. Wong, Stephen James Nicholls, Joanne T. M. Tan, Christina A. Bursill · 2018 · International Journal of Molecular Sciences
39. Application of PCSK9 Inhibitors in Practice
    Tina M. Kaufman, Bruce A. Warden, Jessica Minnier, Joshua Miles, Paul Barton Duell, Jonathan Q. Purnell, Cezary Wójcik, Sergio Fazio, Michael David Shapiro · 2019 · Circulation Research
40. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
    James A. Underberg, Peter Paul Toth, Fátima Rodríguez · 2022 · Postgraduate Medicine
41. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
    Abdul Waheed Khan, Karin Agnes Maria Jandeleit-Dahm · 2025 · Nature Reviews Cardiology
42. Imidazole propionate is a driver and therapeutic target in atherosclerosis
    Annalaura Mastrangelo, Iñaki Robles‐Vera, Diego Mañanes, Miguel Galán, Marcos Femenía-Muiña, Ana Redondo‐Urzainqui, Rafael Barrero-Rodríguez, Eleftheria Papaioannou, Joaquín Amores-Iniesta, Ana Devesa et al. · 2025 · Nature
43. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
    Rósa B. Þórólfsdóttir, Garðar Sveinbjörnsson, Patrick Sulem, Jonas Bille Nielsen, Stefan Jonsson, Gisli Hreinn Halldorsson, Páll Melsted, Erna V. Ivarsdottir, Olafur B. Davidsson, Ragnar P. Kristjansson et al. · 2018 · Communications Biology
44. Recent Progress in Polyhydroxyalkanoates‐Based Copolymers for Biomedical Applications
    Zheng Luo, Yun‐Long Wu, Zibiao Li, Xian Jun Loh · 2019 · Biotechnology Journal
45. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Ji Soo Lee, Partha Mukhopadhyay, Csaba Mátyás, Eszter Trojnár, János Pálóczi, Yuan Ru Yang, Brandon A. Blank, Cody H. Savage, Alexander V. Sorokin, Nehal N. Mehta et al. · 2019 · Scientific Reports
46. High lipoprotein(a): Actionable strategies for risk assessment and mitigation
    Gissette Reyes‐Soffer, Calvin Yeang, Erin D. Michos, Wess Boatwright, Christie Mitchell Ballantyne · 2024 · American Journal of Preventive Cardiology
47. Small molecules as inhibitors of PCSK9: Current status and future challenges
    Xu, Shengtao, Luo, Shanshan, Zhu, Zheying, Xu, Jinyi · 2019 · European Journal of Medicinal Chemistry
48. Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
    Al-Salameh, Abdallah, Chanson, Philippe, Bucher, Sophie, Ringa, Virginie, Becquemont, Laurent · 2019 · Mayo Clinic Proceedings
49. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
    Preiss, David, Tobert, Jonathan A., Hovingh, G. Kees, Reith, Christina · 2020 · Journal of the American College of Cardiology
50. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion
    Zufeng Ding, Xianwei Wang, Shijie Liu, Sichang Zhou, Rajshekhar A. Kore, Shengyu Mu, Xiaoyan Deng, Yubo Fan, Jawahar L. Mehta · 2020 · Theranostics
51. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
    José Tuñón, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema, Yong-Un Kim, Qian H Li, Christian Eugen Mueller et al. · 2020 · European Heart Journal
52. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
    Shunsuke Katsuki, Prabhash Kumar Jha, Adrien Lupieri, Toshiaki Nakano, Lívia Silva Araújo Passos, Maximillian A. Rogers, DAKOTA R. BECKER-GREENE, Thanh-Dat Le, Julius L. Decano, Lang Ho Lee et al. · 2022 · Circulation Research
53. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study
    So Mi Jemma Cho, Satoshi Koyama, Michael C. Honigberg, Ida L. Surakka, Sara Haidermota, Shriienidhie Ganesh, Aniruddh P. Patel, Romit Bhattacharya, Hokyou Lee, Hyeon Chang Kim et al. · 2023 · European Heart Journal
54. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
    Diana De Oliveira-Gomes, Parag H. Joshi, Eric David Peterson, Anand K. Rohatgi, Amit Khera, Ann Marie Návar · 2024 · Circulation
55. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
    Peter Paul Toth, Olivier S Descamps, Jacques J. Genest, Naveed A. Sattar, David Preiss, Ricardo E. Dent, C. Stephen Djedjos, Yuna Wu, Michelle L. Geller, Magdalena Uhart et al. · 2017 · Circulation
56. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents
    Chiara Macchi, Maciej Banach, Alberto Corsini, CR Sirtori, Nicola Ferri, Massimiliano Ruscica · 2019 · European Journal of Preventive Cardiology
57. Next-generation drug repurposing using human genetics and network biology
    Serguei Nabirotchkin, Alexandre E. Peluffo, Philippe Rinaudo, Jinchao Yu, Rodolphe Hajj, Daniel Cohen · 2020 · Current Opinion in Pharmacology
58. Acetaldehyde Dehydrogenase 2 regulates HMG-CoA reductase stability and cholesterol synthesis in the liver
    Shanshan Zhong, Luxiao Li, Ningning Liang, Lili Zhang, Xiaodong Xu, Shiting Chen, Huiyong Yin · 2021 · Redox Biology
59. Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction
    Andreas Schäfer, Tobias König, Johann K Bauersachs, Muharrem Akin · 2022 · Current Problems in Cardiology
60. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial
    Shamir R. Mehta, Guillaume Paré, Eva Lonn, Sanjit S. Jolly, Madhu K. Natarajan, Natalia Pinilla‐Echeverri, Jon-David Schwalm, Tej Sheth, Matthew Sibbald, Michael Tsang et al. · 2022 · EuroIntervention
61. Genetic variant at coronary artery disease and ischemic stroke locus 1p32.2 regulates endothelial responses to hemodynamics
    Matthew D. Krause, Ru‐Ting Huang, David Wu, Tzu‐Pin Shentu, Devin L. Harrison, Michael Bernard Whalen, Lindsey K. Stolze, Anna Di Rienzo, Ivan P. G. Moskowitz, Mete Civelek et al. · 2018 · Proceedings of the National Academy of Sciences
62. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
    Jemma C. Hopewell, Rainer Malik, Elsa Valdés‐Márquez, Bradford B. Worrall, Rory Collins · 2017 · European Heart Journal
63. Optimal Medical Management of Asymptomatic Carotid Stenosis
    Daniel G. Hackam · 2021 · Stroke
64. The potential of polygenic scores to improve cost and efficiency of clinical trials
    Akl C. Fahed, Anthony Philippakis, Amit V. Khera · 2022 · Nature Communications
65. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
    Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim et al. · 2024 · Diabetes & Metabolism Journal
66. Enhancing the Promise of Drug Repositioning through Genetics
    Jayne-Louise Pritchard, Tracy A. O’Mara, Dylan M. Glubb · 2017 · Frontiers in Pharmacology
67. Sex Differences in the Coronary System
    Viviany R. Taqueti · 2018 · Advances in experimental medicine and biology
68. PCSK9: A novel inflammation modulator in atherosclerosis?
    Zhi‐Han Tang, Tao‐Hua Li, Juan Peng, Jie Zheng, Tingting Li, Lushan Liu, Zhi‐Sheng Jiang, Xi‐Long Zheng · 2018 · Journal of Cellular Physiology
69. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
    Stella Bernardi, Annalisa Marcuzzi, Elisa Piscianz, Alberto Tommasini, Bruno Fabris · 2018 · International Journal of Molecular Sciences
70. Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians
    Enas A. Enas, Basil Varkey, Thiruvinvamalai S. Dharmarajan, Guillaume Paré, Vinay Kumar Bahl · 2019 · Indian Heart Journal
71. Lipid Lowering Drugs: Present Status and Future Developments
    Ruscica, Massimiliano, Ferri, Nicola, Santos, Raul D., Sirtori, Cesare R., Corsini, Alberto · 2021 · Current Atherosclerosis Reports
72. PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Aureli Luquero, Lina Badimón, María Borrell-Pagés · 2021 · Frontiers in Cardiovascular Medicine
73. Triglyceride-rich lipoproteins and cardiovascular diseases
    Xu, Dandan, Xie, Lin, Cheng, Cheng, Xue, Fei, Sun, Chaonan · 2024 · Frontiers in Endocrinology
74. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
    Rosenson, Robert S., Daviglus, Martha L., Handelsman, Yehuda, Pozzilli, Paolo, Bays, Harold, Monsalvo, Maria Laura, Elliott-Davey, Mary, Somaratne, Ransi, Reaven, Peter · 2019 · Diabetologia
75. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
    Masato Nakamura, Hitoshi Yaku, Junya Ako, Hirokuni Arai, Tohru Asai, Taishiro Chikamori, Hiroyuki Daida, Kiyoshi Doi, Toshihiro Fukui, Toshiaki Ito et al. · 2022 · Institutional Repositories DataBase (IRDB)
76. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial
    Lalwani, Narendra D., Hanselman, Jeffrey C., MacDougall, Diane E., Sterling, Lulu R., Cramer, Clay T. · 2019 · Journal of Clinical Lipidology
77. Vaccination Strategies and Immune Modulation of Atherosclerosis
    Jan Åke Nilsson, Göran K. Hansson · 2020 · Circulation Research
78. 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care
    Kim K. Birtcher, Larry A. Allen, Jeffrey L. Anderson, Marc P. Bonaca, Ty J. Gluckman, Aliza Hussain, Mikhail Kosiborod, Laxmi S. Mehta, Salim S. Virani · 2022 · Journal of the American College of Cardiology
79. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
    Shailendra B. Patel, Kathleen Louise Wyne, Samina Afreen, Ligia Maria Belalcazar, Melanie D. Bird, Sarah Coles, Joel C. Marrs, Carol Chiung‐Hui Peng, Vishnu Priya Pulipati, Shahnaz Sultan et al. · 2025 · Endocrine Practice
80. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram
    Аверков Олег Валерьевич, GOHAR HARUTYUNYAN, Dmitry Viktorovich Duplyakov, Е. В. Константинова, N. N. Konstantinova, Roman M. Shakhnovich, I. S. Yavelov, Aleksey N. Yakovlev, Abugov Sa, Bagrat G. Alekyan et al. · 2025 · Russian Journal of Cardiology
81. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis
    L. Masana, Josefa Girona, Daiana Ibarretxe, Ricardo Rodríguez‐Calvo, Roser Rosales, Joan-Carles Vallvé, Cèlia Rodríguez-Borjabad, Montse Guardiola, M. Mar Rodríguez, Sandra Guaita‐Esteruelas et al. · 2018 · Journal of clinical lipidology
82. Role of PCSK9 in lipid metabolism and atherosclerosis
    Xiaolong Lin, Lele Xiao, Zhi‐Han Tang, Zhi‐Sheng Jiang, Mi‐Hua Liu · 2018 · Biomedicine & Pharmacotherapy
83. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up
    Mathijs C. Bodde, Maaike P. J. Hermans, J. Wouter Jukema, Martin Jan Schalij, Willem M. Lijfering, Frits Richard Rosendaal, Fred P.H.T.M. Romijn, L. Renee Ruhaak, Arnoud van der Laarse, Christa M. Cobbaert · 2018 · Clinical Research in Cardiology
84. Cardiovascular Protection in People With Diabetes
    James A. Stone, Robyn L. Houlden, Peter Lin, Jacob Allen Udell, Subodh Verma · 2018 · Canadian Journal of Diabetes
85. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
    Shaun G. Goodman, Philip E. Aylward, Michael J. Szarek, Vakhtang Chumburidze, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Jay M. Edelberg, Corinne Hanotin, Robert A. Harrington et al. · 2019 · Journal of the American College of Cardiology
86. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome
    Heinz Drexel, Andrew J.S. Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M.C. Rosano · 2019 · European Heart Journal - Cardiovascular Pharmacotherapy
87. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease
    Francine K. Welty · 2020 · Current Opinion in Lipidology
88. Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
    Marc Wolf, Patrick Hunziker · 2020 · Journal of Cardiovascular Translational Research
89. Caspase-11-Gasdermin D-Mediated Pyroptosis Is Involved in the Pathogenesis of Atherosclerosis
    Mengqing Jiang, Xuejing Sun, Suzhen Liu, Yan Jun Tang, Yunming Shi, Yuanyuan Bai, Yujie Wang, Qiong Yang, Qize Yang, Weihong Jiang et al. · 2021 · Frontiers in Pharmacology
90. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
    Eunhye Ji, Sahmin Lee · 2021 · International Journal of Molecular Sciences
91. Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients
    Jiejie Li, Yuesong Pan, Jie Xu, Shiyu Li, Mengxing Wang, Kehua Quan, Xia Meng, Hao Li, Jinxi Lin, Yilong Wang et al. · 2021 · Stroke
92. Guidance for the diagnosis and treatment of hypolipidemia disorders
    Cindy Bredefeld, M. Mahmood Hussain, Maurizio Rocco Averna, Dennis D. Black, Mitchell F. Brin, John R. Burnett, Sybil Charrière, Charlotte Cuerq, Nicholas O. Davidson, Richard Joseph Deckelbaum et al. · 2022 · Journal of clinical lipidology
93. Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
    Stefan Živković, Gorica D. Maric, Nataša Cvetinovic, Danijela Lepojevic-Stefanovic, Bojana Božić · 2023 · Nutrients
94. Therapeutic Antibodies in Medicine
    Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu, Maya A. Eicher · 2023 · Molecules
95. Therapeutic Targeting in Nanomedicine: the Future Lies in Recombinant Antibodies
    Geoffrey A. Pietersz, Xiaowei Wang, May Lin Yap, Bock Lim, Karlheinz Peter · 2017 · Nanomedicine
96. Relative effects of LDL-C on ischemic stroke and coronary disease
    Elsa Valdés‐Márquez, Sarah Parish, Robert Clarke, Traiani Stari, Bradford B. Worrall, Jemma C. Hopewell · 2019 · Neurology
97. PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
    Alanna M. Chamberlain, Yan Gong, Kathryn M. Shaw, Jiang Bian, Wen‐Liang Song, MacRae F. Linton, Vivian Andrew Fonseca, Eboni G. Price‐Haywood, Emily Guhl, Jordan B. King et al. · 2019 · Journal of the American Heart Association
98. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis
    Khan, Safi U., Rahman, Hammad, Okunrintemi, Victor, Riaz, Haris, Khan, Muhammad Shahzeb, Sattur, Sudhakar, Kaluski, Edo, Lincoff, A. Michael, Martin, Seth S., Blaha, Michael J. · 2019 · Journal of the American Heart Association
99. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials
    Khan, Safi U, Khan, Muhammad U, Valavoor, Shahul, Khan, Muhammad Shahzeb, Okunrintemi, Victor, Mamas, Mamas A, Leucker, Thorsten M, Blaha, Michael J, Michos, Erin D · 2020 · European Journal of Preventive Cardiology
100. Dyslipidemia
     Mancini, G.B. John, Hegele, Robert A., Leiter, Lawrence A. · 2018 · Canadian Journal of Diabetes